ReviewNon-coding RNA research2026
LncRNA ZFAS1 in hepatocellular carcinoma: A systematic review of molecular mechanisms and clinical translation.
Review in Non-coding RNA research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- The regulatory mechanisms and clinical translation potential of RNA-binding protein RALY in tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with its high recurrence rate and therapeutic resistance underscoring the urgent need for breakthrough molecular targets. The long non-coding RNA ZFAS1 has emerged as a critical regulatory hub in HCC pathogenesis through its multidimensional mechanisms. Clinical investigations reveal significant ZFAS1 overexpression in HCC tissues, which is strongly associated with microvascular invasion, lymph node metastasis, and unfavorable clinical outcomes. Meta-analytical data further corroborate its independent prognostic value in survival prediction. Mechanistically, ZFAS1 functions as a competitive endogenous RNA (ceRNA) that sequesters tumor-suppressive miRNAs including miR-150 and miR-193a-3p, thereby de-repressing downstream oncogenic targets such as ZEB1/MMP14 and RALY/HGF/c-Met. This molecular interplay drives epithelial-mesenchymal transition (EMT) and metastatic progression, while ZFAS1-encoded micropeptides concurrently inhibit ferroptosis through mitochondrial ROS modulation and the miR-150/AIFM2 axis, thereby synergistically enhancing tumor proliferation and apoptotic resistance. Within the tumor microenvironment (TME), exosome-derived ZFAS1 remodels intercellular communication networks, promoting angiogenesis via STAT3/VEGFA signaling, though its immunometabolic regulatory mechanisms warrant further elucidation. Clinically, plasma ZFAS1 demonstrates enhanced diagnostic utility when combined with alpha-fetoprotein (AUC = 0.891), while therapeutic targeting of ZFAS1-mediated PI3K-AKT and PERK/ATF4 pathways shows promise in overcoming sorafenib/donafenib resistance. Current translational challenges include ZFAS1 isoform heterogeneity, suboptimal liquid biopsy sensitivity, and dynamic TME interactions. Future directions should employ multi-omics integration (spatial transcriptomics/single-cell sequencing) coupled with AI-driven network modeling to systematically decode ZFAS1's regulatory architecture, ultimately enabling precision theranostic strategies for HCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.